investor relations

Investment Highlights

• Strong management and board experience with more than 10 drug regulatory approvals worldwide
• Late stage proprietary gastro-intestinal compound with four indications - AIDS diarrhea, Irritable Bowel Syndrome (IBS), acute infectious diarrhea and pediatric diarrhea
• FDA fast-track status for AIDS diarrhea and IBS products
• Extensive safety data on more than 1500 patients across all indications
• Global business model with multiple corporate partners covering all four clinical indications in all countries
• Focus on profitability in Western markets and emerging economy populations for large product volume and financial return
• Crofelemer sustainably harvested from medical rainforest plant - benefit sharing contribution in place to recognise indigenous knowledge and environmental responsibility
• Pipeline product for metabolic syndrome